The Feasibility Study of Adjuvant Chemotherapy with TS-1+Carboplatin followed by TS-1 maintenace in Patients with Completely Resected Stage II-IIIA Non-Small-Cell Lung Cancer

The Feasibility Study of Adjuvant Chemotherapy with TS-1+Carboplatin followed by TS-1 maintenace in Patients with Completely Resected Stage II-IIIA Non-Small-Cell Lung Cancer - The Feasibility Study of Adjuvant TS-1+ Carboplatin and TS-1 Maintenance in Patients with Resected Stage II-IIIA Non-Small-Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005041

Enrollment

Registered

2011-02-07

Start date

2011-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

Carboplatin (5AUC) (day 1) + S-1 (80mg/m2) (day 1-14) q4weeks, 4 cycles Maintenace S-1 (80mg/m2) (day 1-14) q3weeks, 8 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically determined non-small cell lung cancer 2. Completely resected (more than lobectomy + ND2a) 3. Pathological stage IIA, IIB, IIIA 4. Neither previous chemotherapy nor radiotherapy before operation 5. Aged 20-74 years old 6. ECOG performance status 0 or 1 7. Adequate organ function 8. Possible to receive chemotherapy within 8 months after surgery 9. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Allergy against platinum-containing drugs or component of S-1 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, uncontrolled diabetes, ileus, diarrhea, hemorrhagic tendency) 3. Active infections 4. Massive pleural or pericardial effusion 5. Active simultaneous cancer 6. Active interstitial pneumonitis or its past history 6. Pregnant or lactating women 8. Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Feasibility	—

Secondary

Measure	Time frame
disease free survival, overall survival	—

Countries

Japan

Contacts

Public ContactShinichi Toyooka

Setouchi Lung Cancer Group Dept. of Thoracic, Breast & Endocrine Surgery, Okayama Univ. Grad. Sch. Med., Dent. & Pharma. Sci.

toyooka@md.okayama-u.ac.jp086-235-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026